Victor Altadonna
Urology · Lancaster, PANPI 1558393611
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,883 and has fallen 98.6% since, to $27 in 2024.
Across 177 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$638
- Astellas Pharma US Inc$516
- Dendreon Pharmaceuticals LLC$306
- AstraZeneca$181
- Ferring Pharmaceuticals Inc.$174
- Johnson & Johnson$155
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,423100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 1 | $638 |
| Astellas Pharma US Inc | 40 | $516 |
| Dendreon Pharmaceuticals LLC | 12 | $306 |
| AstraZeneca | 9 | $181 |
| Ferring Pharmaceuticals Inc. | 16 | $174 |
| Johnson & Johnson | 11 | $155 |
| Bayer | 10 | $140 |
| Merck | 8 | $137 |
| AbbVie(2 entities) | 5 | $116 |
| Travere Therapeutics, Inc. | 7 | $115 |
| Coloplast | 6 | $106 |
| Sun Pharmaceutical Industries Inc. | 5 | $92 |
| Tolmar Pharmaceuticals, Inc. | 4 | $80 |
| Myriad Genetic Laboratories, Inc. | 6 | $74 |
| Axonics, Inc. | 5 | $70 |
| Pfizer | 5 | $70 |
| Foundation Medicine, Inc. | 3 | $67 |
| Urogen Pharma, Inc. | 4 | $48 |
| Urovant Sciences Inc | 3 | $47 |
| Antares Pharma, Inc. | 2 | $43 |
| 180 Medical, Inc. | 2 | $35 |
| Blue Earth Diagnostics | 1 | $28 |
| Myovant Sciences Inc. | 2 | $25 |
| Verity Pharmaceuticals Inc. | 2 | $25 |
| Boston Scientific | 1 | $22 |
| Baxter Healthcare | 1 | $20 |
| Rochester Medical Corporation | 1 | $20 |
| EMD Serono, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Olympus America Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,423 in reported general payments places this provider in the 60th percentile of 596 urology providers in Pennsylvania.
Other urology in Lancaster
- Paul SieberLancaster$631K
- Christopher MillerLancaster$19K
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.